Konrad T, Bloechle C, Haller G, Broelsch C E, Usadel K H, Kusterer K
Center of Internal Medicine, University of Frankfurt, Germany.
Res Exp Med (Berl). 1995;195(2):61-8. doi: 10.1007/BF02576775.
Using the model of the isolated perfused rat liver, we investigated the influence of the two pharmacologically different calcium channel blockers, verapamil and flunarizine, on changes of ion homeostasis, liver weights, pH deviations and enzyme activities during warm ischemia (37 degrees C) and reperfusion. The LDH and GLDH activities were determined and the calcium, potassium, and sodium concentrations were measured in the effluent. Warm ischemia (180 min) caused an increased enzyme release, a high influx of calcium and sodium into the liver and a massive potassium efflux current. Normoxic reperfusion led to a further increase in hepatic enzyme release and although the loss of potassium ceased, the calcium influx into the liver continued. By the end of reperfusion the liver weight had increased significantly (P < 0.01) in the control group. The two calcium entry blockers were added to the perfusate in various concentrations. Both substances protected the liver against warm ischemia and normoxic reperfusion damage, but they did not inhibit calcium inflow. However, the potassium efflux was significantly reduced by all concentration tasted (P < 0.001). After reperfusion the liver weights were significantly lower in the treated groups (P < 0.001) than in control animals. Thus, the calcium entry blockers verapamil and flunarizine protect liver cells against damage caused by warm ischemia and reperfusion. Furthermore, they prevent the disruption of intracellular potassium homeostasis, which seems to be related to improved volume regulation of liver cells.
利用离体灌注大鼠肝脏模型,我们研究了两种药理作用不同的钙通道阻滞剂维拉帕米和氟桂利嗪对热缺血(37℃)及再灌注期间离子稳态变化、肝脏重量、pH偏差和酶活性的影响。测定了流出液中的乳酸脱氢酶(LDH)和谷氨酸脱氢酶(GLDH)活性,并测量了钙、钾和钠的浓度。热缺血(180分钟)导致酶释放增加、钙和钠大量流入肝脏以及大量钾外流。常氧再灌注导致肝脏酶释放进一步增加,尽管钾流失停止,但钙流入肝脏仍在继续。再灌注结束时,对照组肝脏重量显著增加(P < 0.01)。将两种钙通道阻滞剂以不同浓度加入灌注液中。两种物质均能保护肝脏免受热缺血和常氧再灌注损伤,但它们并不抑制钙流入。然而,所有测试浓度均显著降低了钾外流(P < 0.001)。再灌注后,治疗组的肝脏重量显著低于对照动物(P < 0.001)。因此,钙通道阻滞剂维拉帕米和氟桂利嗪可保护肝细胞免受热缺血和再灌注造成的损伤。此外,它们可防止细胞内钾稳态的破坏,这似乎与改善肝细胞的容积调节有关。